TITLE

Acute leukemia after infliximab therapy

AUTHOR(S)
Alcaín, Guillermo; Andrade, Raúl J.; Queipo de Llano, María P.; Moreno, María J.; García-Cortés, Miren; Franquelo, Eduardo
PUB. DATE
November 2003
SOURCE
American Journal of Gastroenterology;Nov2003, Vol. 98 Issue 11, p2577
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
No abstract available.
ACCESSION #
11469070

 

Related Articles

  • Azathioprine/infliximab.  // Reactions Weekly;2/6/2016, Vol. 1587 Issue 1, p64 

    An abstract of the article "A case of acute myeloid leukemia (M4) with myeloid sarcoma after infliximab and azathioprine combination therapy in Crohn's disease" by S-H Choi and others is presented.

  • Thyroid Cancer and T Lymphoblastic Leukemia in Crohn Disease: A Case Report and Literature Review. Ja Min Byun; Sun Kyung Baek; Hwi-Joong Yoon; Si-Young Kim; Chi Hoon Maeng; Tae Sung Park; Hyo-Jong Kim; Yun Young Choi; Yu Jin Um // Laboratory Medicine;Spring2015, Vol. 46 Issue 2, p140 

    The effectiveness of the tumor necrosis--α (TNF-α) blockade has changed the treatment of several chronic inflammatory diseases, including inflammatory bowel disease; however, this treatment also has disadvantages. The use of immunosuppressants in combination with infliximab has been...

  • Gemtuzumab ozogamicin.  // Reactions Weekly;1/8/2011, Issue 1333, p22 

    The article describes cases of toxicities in elderly patients with acute myelogenous leukemia after receiving postremission therapy with gemtuzumab ozogamicin.

  • Online Quiz Questions: Genomic Assessment of Mutation Clearance After Induction Therapy and Outcomes In Acute Myeloid Leukemia.  // JAMA: Journal of the American Medical Association;8/25/2015, Vol. 314 Issue 8, p829 

    A quiz is presented concerning genomic assessment of mutation clearance after the use of induction therapy and outcomes for acute myeloid leukemia.

  • Infliximab.  // Reactions Weekly;1/21/2012, Issue 1385, p25 

    The article describes the case of a 56-year-old man with active Crohn's disease (CD) and acute extraintestinal manifestations who developed sinusitus after receiving infliximab therapy.

  • Fludarabine.  // Reactions Weekly;Nov2014, Vol. 1529 Issue 1, p103 

    An abstract of the article "Therapy-related acute myeloblastic leukemia after splenectomy in a patient with composite lymphoma developing after treatment of chronic lymphocytic leukemia," by T. Valkovic and colleagues is presented.

  • EORTC Protocol 06023--Infliximab.  // Oncologie;sep2004 Supplement 7, Vol. 6, pS191 

    Presents information on a clinical trial on the use of infliximab in patients with myelodysplastic syndrome and a low risk of developing acute leukemia. Experimental procedure; Results; Objectives.

  • Managing Immunogenic Responses to Infliximab: Treatment Implications for Patients with Crohn’s Disease. Han, Peter D.; Cohen, Russell D. // Drugs;2004, Vol. 64 Issue 16, p1767 

    Infliximab is a tumour necrosis factor (TNF)-α antagonist that has revolutionised the treatment of Crohn’s disease and rheumatoid arthritis. However, infliximab therapy can be complicated by a variety of adverse reactions. Acute infusion reactions occur during or shortly after infusion...

  • Capecitabine.  // Reactions Weekly;May2014, Vol. 1500 Issue 1, p11 

    An abstract of the article "Therapy-related acute promyelocytic leukemia after chemoradiotherapy with capecitabine for rectal adenocarcinoma," by A. Rashidi and colleagues is presented.

  • Therapy of older persons with acute myeloid leukemia. Gale, R P; Hochhaus, A // Leukemia (08876924);Apr2015, Vol. 29 Issue 4, p759 

    The article discusses the therapy of older persons with acute myeloid leukemia.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics